Neogenomics: Grant Carlson has been appointed Vice President of Business Development. In addition, Mark Smits will join the company as Vice President of Sales & Marketing on August 30. In the new role, Carlson will be responsible for developing key business relationships and revenue opportunities for short-term performance and long term growth objectives. Most recently, Smits spent nearly two years with Thermo Fisher as the Vice President for the Fisher Healthcare Division where he successfully led their sourcing and business development efforts. [August 2010]

The Blackstone Group: Health policy and financing expert Robert Galvin, M.D., has joined Blackstone (New York City) as CEO of Equity Healthcare, the health management program that aims to improve quality and contain costs in providing healthcare to the employees and their families of the firm's private equity portfolio companies. Galvin previously served as executive director of health services and chief medical officer for General Electric. [August 2010]

Banyan Biomarkers: Lynda Haguehas been appointed vice president of clinical and regulatory affairs at Banyan Biomarkers (Alachua, Fla.), which is developing in vitro diagnostic products to detect traumatic brain injury. She was previously director of clinical research at Abbott Molecular. [August 2010]

DiagnoCure: Chantal Miklosi has been appointed chief financial officer (CFO) of DiagnoCure(Quebec City), which commercializes and performs molecular diagnostic tests to detect and manage cancer. Miklosi previously served as marketing director and CFO at JMP Securities in San Francisco. She takes over from senior director Frédéric Boivin, who served as interim CFO following the March departure of Jean-François Bureau. [July 2010]

Illumina: B. Melina Cimler, Ph.D., has been appointed vice president of quality and regulatory affairs at Illumina (San Diego), where she will lead the company's quality and regulatory organizations to support the development, manufacture, and distribution of products serving the research, consumer, and molecular diagnostic markets. Cimler was previously president of PandiaDx Consulting. [July 2010]

Illumina: Nicholas J. Naclerio, Ph.D., has been appointed senior vice president of corporate development at Illumina (San Diego). He will be responsible for all corporate and business development activities, including licensing, strategic planning, and acquisitions. Before joining Illumina, Naclerio co-founded and served as executive chairman of development-stage diagnostics company Quanterix. [July 2010]

Hycor Biomedical: Steve Johnson has been appointed director of quality and regulatory affairs at Hycor Biomedical (Garden Grove, Calif.), the IVD company that was acquired in February by private equity firm Linden. Johnson is a 25-year veteran of Abbott Laboratories, where he most recently served as site quality head and management representative at the company's South Pasadena facility. [July 2010]

Hycor Biomedical: Mark Van Cleve, Ph.D., has been appointed director of research and development at Hycor Biomedical(Garden Grove, Calif.). He was previously applications development manager at Agilent Technologies, Hycor's former parent company, where he managed process/product engineering and R&D for the Hycor division and managed a team of scientists. [July 2010]

Immucor: G. Mason Morfit has been appointed to the board of directors of Immucor (Norcross, Ga.), maker of instruments and reagents for blood screening. Morfit is a partner with the investment management firm ValueAct Capital. [July 2010]